AbbVie One Step Closer to Interferon-Free Therapy for Hepatitis C
February 4, 2014
AbbVie completes Phase III trial program for treatment of hepatitis C genotype 1
PBR Staff Writer Published 03 February 2014
AbbVie has completed its Phase III clinical trial program and released results of four additional studies designed to assess its investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.
Hepatitis C’s Impact – From Head to Toe
5 Hep C-Friendly Essential Oils for Valentine’s Day